Pharmaceutical composition for treating cancer comprising microrna as active ingredient
US-2018030440-A1 · Feb 1, 2018 · US
Kit, device and method for detecting prostate cancer
US11535899B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11535899-B2 |
| Application number | US-201917265060-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 9, 2019 |
| Priority date | Aug 10, 2018 |
| Publication date | Dec 27, 2022 |
| Grant date | Dec 27, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for detecting prostate cancer and then treating or performing a diagnostic procedure in a human subject, comprising: measuring an expression level of has-miR-1185-1-3p in a blood, serum, or plasma sample from the subject; comparing the measured expression level of hsa-miR-1185-1-3p to a control expression level in a sample from a healthy subject; and detecting an increased level of hsa-miR-1185-1-3p in the sample from the subject as compared to the control expression level from the sample from the healthy subject, wherein the increased level of hsa-miR-1185-1-3p indicates that the subject has prostate cancer, and and further treating the subject for the prostate cancer or performing a diagnostic procedure on the subject with the prostate cancer; wherein the treating comprises surgery, radiotherapy, chemotherapy or the combination thereof; and wherein the diagnostic procedure comprises rectal examination, transrectal ultrasonography of the prostate, or imaging of prostate tissue. 2. The method according to claim 1 , wherein the expression level of hsa-miR-1185-1-3p in the sample is measured by using a kit comprising a nucleic acid(s) that specifically binds to hsa-miR-1185-1-3p. 3. The method according to claim 1 , wherein the expression level of hsa-miR-1185-1-3p in the sample is measured by using a device comprising a nucleic acid(s) that specifically binds to hsa-miR-1185-1-3p. 4. The method according to claim 3 , wherein the device further comprises at least one nucleic acid capable of specifically binding to at least one polynucleotide selected from the following other prostate cancer markers: miR-1185-2-3p, miR-197-5p, miR-6076, and/or miR-17-3p, miR-320b, miR-6819-5p, and miR-1228-5p.
Assignees
Inventors
Classifications
miRNA, siRNA or ncRNA · CPC title
- C12Q1/6886Primary
for cancer (immunoassay for cancer G01N33/575) · CPC title
Expression markers · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11535899B2 cover?
- This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in…
- Who is the assignee on this patent?
- Toray Industries, Nat Cancer Ct
- What technology area does this patent fall under?
- Primary CPC classification C12Q1/6886. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).